Aikaterini Amaniti, Ioannis Dalakakis, Dimitrios Gkinas, Konstantinos Sapalidis, Vasilios Grosomanidis, George Papazisis
AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Laboratory of Pharmacology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Case Rep Anesthesiol. 2018 Dec 5;2018:2896032. doi: 10.1155/2018/2896032. eCollection 2018.
Dexmedetomidine is an elective alpha-2 adrenergic agonist, being used in anesthesia practice. It offers sedative, anxiolytic, analgesic, muscle relaxant, and sympathetic lytic properties. While respiratory effects are considered minor, there are important cardiovascular side effects with bradycardia and hypotension being the most common. This article presents a case of a patient, with significant comorbidities and polypharmacy, who was scheduled for cataract surgery under dexmedetomidine sedation. During the administration, severe hemodynamic deterioration was observed with bradycardia and hypotension leading to asystole. Cardiac arrest was successfully managed in accordance with the guidelines of the European Resuscitation Council. Despite the promising role of dexmedetomidine in anesthesia practice, the associated adverse effects cannot be ignored. For this reason it is obligatory to have the minimum mandatory monitoring in accordance with the safety and quality guidelines.
右美托咪定是一种选择性α-2肾上腺素能激动剂,用于麻醉实践。它具有镇静、抗焦虑、镇痛、肌肉松弛和交感神经阻滞作用。虽然呼吸影响被认为较小,但存在重要的心血管副作用,最常见的是心动过缓和低血压。本文介绍了一例有严重合并症和多种药物治疗史的患者,计划在右美托咪定镇静下进行白内障手术。给药期间,观察到严重的血流动力学恶化,伴有心动过缓和低血压导致心脏停搏。根据欧洲复苏委员会的指南,心脏骤停得到了成功处理。尽管右美托咪定在麻醉实践中具有前景,但相关的不良反应不容忽视。因此,必须按照安全和质量指南进行最低限度的强制监测。